Phathom upgraded at Barclays following pullback, Voquezna optimism

What: Phathom Pharmaceuticals Inc. (KYPH) has been upgraded by Barclays after a recent pullback, driven by optimism surrounding its Voquezna product.
Why: The upgrade is based on the company's strong pipeline, particularly its Voquezna product, which has shown promising results.
Signal: The upgrade is seen as a positive signal for the company's future prospects, indicating a potential rebound in its stock price.
Target: Barclays has set a price target of $**15.00** for Phathom Pharmaceuticals Inc.
Risk: The upgrade carries some risk, as the company's stock price may not necessarily reach the target, and market conditions can change rapidly.